ATTENTION: Please enable Javascript in your browser for full site functionality.
Skip to navigation Skip to main content Skip to footer

Ticker Update

Updates

SUB-TYPE: PRESS RELEASES

New State-of-the Art Warehouse Facility for Alloga UK

Alloga UK, one of the country’s leading healthcare pre-wholesaling and contract logistics companies, is to open another state-of-the art warehouse facility in the East Midlands.

 

Alloga UK provides supply chain solutions to the healthcare industry, offering specialist storage, fulfilment and distribution services for pharmaceutical, healthcare, medical device, veterinary and consumer product manufacturing companies. 

 

Alloga UK’s operations are currently based in South Normanton, with eight pharma-grade warehouses and the company’s strategy is one of growth and continued investment for a sound future for the business and its employees.

 

The company now needs to further expand its storage and distribution capacity in order to accommodate growth from new business wins, post Brexit and Covid-19 stock builds and increase in volumes from existing clients to provide capacity for continued growth beyond 2020.

                   

Alloga UK is now delighted to announce that a new site will be added to their current warehouse portfolio, and is planned to be fully commissioned and operationally live in mid-2021.

 

Currently named  Derby 370, this new site, which will be known as AP8, is located on Derby Commercial Park which is 20 miles south of the Alloga Campus with good links to the M1 motorway and two miles east of the city of Derby facilitating good access to the working population. The distribution site has been developed by the owners, Panattoni (the world’s largest privately owned industrial developer) and it is significantly larger than Alloga’s existing warehouses, allowing them much needed new capacity for sustained future growth.

 

The specification of the site includes:

- Total size of 371,000 sq ft (34,466 sq m)

- 15 metres to haunch

- Capacity for c.70,000 pallets of storage (euro pallets)

- BREEAM = Very Good status

- Administration offices over three floors

- Warehouse office hub over two floors

- 74 HGV lorry parking spaces and 270 car parking spaces

- 24 dock level doors, eight Double Deck docks and three level access doors

 

Chris Williams, Managing Director of Alloga UK, states: “It is always fantastic news when we open new facilities, and Derby 370 is particularly exciting because it will be our largest warehouse and the first warehouse which is not located in South Normanton.

 

It gives us the opportunity to expand the capabilities of our pre-wholesale business, and further increase job opportunities for existing staff and also new skilled and talented staff from the Derby area.

 

“Our capabilities and service offering for our customers, and manufacturer partners, will continue to evolve with this considerable investment, which will also further enhance our ability to provide innovative solutions and services to meet the ever changing needs of our clients.”

 

 Derby

SUB-TYPE: CORPORATE NEWS

Alliance Healthcare is proudly celebrating Diwali

Across our business, we have a workforce that is diverse and rich in culture, much like our customer base.

 

In the spirit of this, we have put together a short video featuring our team member Marni Gill, who shares whatDiwali is and what it means for him.

 

Have a look at our celebration video!

dwali

 

Our Managaing Director, Julian Mount, also features in this month’s Pharmacy Business Diwali special, alongside pharmacists and pharmacy leaders, sharing hopes and aspirations for the year ahead, as well as reflecting on the year that has passed.

 

On behalf of all of us at Alliance Healthcare, we wish a happy Diwali to all those who celebrate.

SUB-TYPE: CLASS 2 RECALL

CLASS 2 RECALL - ANCOTIL 2.5 G/250 ML SOLUTION FOR INFUSION

: Mylan UK Healthcare Ltd has been informed of a non-compliance event which occurred during the most recent inspection at the contract manufacturing site for the above product in relation to product sterility. As a precautionary measure, remaining stock of the above batches are being recalled.

PIP Code

Product Description

Supplier

Affected Batch

2116432

ANCOTIL INF

MYLAN UK HEALTHCARE

113987

114626

114711

115051

F20CBJ

                                                               

For more information or medical information enquiries please contact Mylan UK Healthcare Ltd Medical Information Department on +44(0) 1707 853000 or via email at Info.uk@mylan.co.uk.

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies

 

This recall will remain open for 3 months from the date issued unless an alternative date is agreed by instigator. The closure of this will be 12/02/2021. Please note after this date customer returns may still be accepted but customers may not be credited.

SUB-TYPE: CLASS 2 RECALL

CLASS 2 RECALL - Sodiofolin 50mg/ml Solution for Injection 100mg/2ml

medac Pharma LLP is recalling the below batch of products due to some inspected vials showing hairline damage to the shoulder of the vials. So far, the company has not received any reports of damage for marketed products. However, as this defect may impact on the sterility of the product, the above batch is being recalled as a precautionary measure

PIP Code

Product Description

Supplier

Affected Batch

Alliance do not stock

Sodiofolin 50mg/ml Solution for Injection 100mg/2ml

Medac Pharma LLP

B190132C

                                                               

Please note that Alliance Healthcare do not stock and we are not accepting stock returns.

 

For more information or medical information queries, please contact info@medacpharma.co.uk or telephone 01786 458086

 

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

If you have any questions, then please contact your local Service Centre Customer Services team

SUB-TYPE: CLASS 4 CAUTION IN USE

Class 4 Drug Caution in use - Kolanticon Gel

Intrapharm Laboratories Ltd has informed us that there is a difference in dosage instructions between the carton and label. The Patient Information Leaflet (PIL) and bottle label contain the correct instructions.

PIP Code

Product Description

Supplier

Affected Batch

0077362

KOLANTICON GEL

INTRAPHARM LABORATORIES

AA0620

This may have been supplied by AHDL. Unfortunately we are not providing specific batch information you will  be required to follow the instructions as per the drug alert.

This is a caution in use only we are not accepting stock returns.

For more information or medical information queries, please contact: medinfo@intrapharmlabs.com or telephone +44 (0)330 1359 437.

 

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

If you have any questions, then please contact your local Service Centre Customer Services team

SUB-TYPE: CORPORATE NEWS

Alcura achieves data security certification

The International Organization for Standardization (ISO) has accredited Alcura with its prestigious data security standard  

 

Alcura, our patient care business, has worked tirelessly over the last few years to ensure patient data is protected and that all its systems and processes are secure and stable.

 

The hard work has paid off as the business has been awarded with a data security accreditation, known as the ISO27001, from the International Organization for Standardization (ISO) – an independent, non-governmental organisation for international standards in areas such as quality, health and safety, IT security, energy, and environmental management.

 

It’s not easy to achieve but it’s an important one for hospital trusts and manufacturer partners as it demonstrates that data security is taken seriously by the business. And this will strengthen Alcura’s position when submitting tenders. It’s also the team’s third ISO accreditation as they already have the Quality Management (ISO9001) and Environmental Management (ISO14001) certifications.

 

Commenting on the team’s latest achievement Simon Jones, Head of Homecare and Secondary Care, says: “We work very closely with the NHS and a number of hospital trusts, and support over 34,000 homecarepatients. We have a special responsibility to look after our patients and we take protecting their data seriously. I’m very proud of the team for attaining this endorsement as it’s one of the hardest to achieve.” 

 

Alcura’s work on data protection was also acknowledged in 2019 as they won an internal WBA award for a data privacy project with Boots, which enabled HIV patients to collect their medication anonymously.

SUB-TYPE: PRESS RELEASES

Walgreens Boots Alliance and McKesson Complete the Formation of German Wholesale Joint Venture

Joint venture demonstrates innovative strength of two companies with impressive and trusted healthcare heritage in the German wholesale market

 

Deerfield, Ill. and Irving, Texas, Nov. 2, 2020

Walgreens Boots Alliance (Nasdaq: WBA) and McKesson Corporation (NYSE: MCK) today announced the completion of their previously announced agreement to create a joint venture combining their respective pharmaceutical wholesale businesses in Germany, Alliance Healthcare Deutschland (AHD) and GEHE Pharma Handel (GEHE). WBA holds a 70 percent controlling equity interest in the joint venture and McKesson holds the remaining 30 percent interest.

 

“At Walgreens Boots Alliance, we all look forward to working together with McKesson Corporation on this joint venture,” said Ornella Barra, co-chief operating officer, Walgreens Boots Alliance. “It is a very exciting step for our Pharmaceutical Wholesale Division and a unique chance for us to further develop innovative services to manufacturers and pharmacists in Germany.”

 

“The completion of this strategic partnership with Walgreens Boots Alliance enables us to strengthen and secure the future of pharmaceutical distribution in the German market,” said Kevin Kettler, chairman of the management board and president McKesson International. “Together, we look forward to delivering a successful model of operations to benefit the German healthcare ecosystem of patients, pharmacies and manufacturers.”

 

With future challenges in the healthcare sector, the new company is committed to strengthening the pharmacist's position as a healthcare professional, creating innovative added value services and significantly enhancing digitalisation and operational excellence.

SUB-TYPE: CLASS 3 RECALL

Class 3 recall - Alfad 0.25 Microgram Capsules

Further to Drug Alert EL (20)A/46 issued on 29 September 2020 Theramex Ireland Ltd T/A Theramex HQ UK Ltd has informed us of an issue related to error in the decommissioning of a further batch as listed above. Upon decommissioning at the pharmacy and when scanning the serialised 2D code, the status of packs may report as ‘EXPORT’. Although there is no risk to product quality, any remaining stock should be quarantined and returnedThe affected products' details are as follows:

PIP Code

Product Description

Supplier

Affected Batch

7149503

ALFAD 0.25 MICROGRAM CAPSULES

THERAMEX

A04279A

 

Please note that Alliance do not stock the above products therefore we are not accepting returns on this recall.

 

For stock control enquiries please contact Theramex HQ UK Ltd Customer Services Team on 020 3962 5532.

 

For medical information enquiries please contact Theramex HQ UK Ltd Medical Information Department on 033 3009 6795.

 

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

SUB-TYPE: PRESS RELEASES

Alliance Healthcare to Reduce Single-Use Plastic by 60% in Three Years

Alliance Healthcare in the UK has announced its promise to reduce single-use secondary plastic within the business by 60% within three years, as part of its “Getting drastic with plastic” campaign. The plastics saving initiatives have been live within the business since 2019 and even the adverse effects of the COVID-19 pandemic have not stopped progress.

 

Alliance Healthcare UK recently started to roll out new reusable tote bins to replace plastic bags and cardboard packaging to its Health and Beauty customers, as part of the initial initiatives to reduce plastic. Julian Mount, Managing Director said: “We recognise that as an industry leader we must pioneer the way in reducing our impact on the environment. Our three year plan will entail an ambitious 35% reduction of single-use plastic secondary packaging by September 2021.”

 

The work being carried out across the entire workforce includes: removal of invoice bags, switching to paper bubble wrap and investment in reusable totes.

 

Jon Cornforth, Environment, Health and Safety Manager says: “Every year, over 2 million units of single-use plastic bags and cardboard boxes will be removed from our operations, considerably lessening Alliance Healthcare’s carbon footprint.”

 

To date, Alliance Healthcare UK has already saved over 39 tonnes and by the close of fiscal-year 2021 will have saved 131 tonnes. The aim is to have reduced the overall use of single-use secondary plastic by an impressive 60% by September 2022.

 

Alliance Healthcare UK team members will mark the launch of the “Getting drastic with plastic” campaign with installations at each of its 14 Service Centre sites across the UK, where colleagues can learn about the promise and get involved with the local initiatives whilst also considering their own day to day behaviours that may impact the environment and making a commitment to the planet. The installation will be produced from completely plant-based materials to go along with the ecological theme of the action.

 

plastic

SUB-TYPE: CLASS 2 RECALL

COMPANY LED - CLASS 2 RECALL Class type: Company Led

Precautionary recall following mould being identified in a few jars of each batch.

 

The affected products' details are as follows:

PIP Code

Product Description

Supplier

Affected Batch

3735883

POTTERS MALT EXT & CLO ORIG

CEUTA

3M01134

3M01136

3M01137

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies

 

Recipients of this Drug Alert should bring it to the attention of relevant contacts.